ANTIEPILEPTIC DRUGS MARKET ANALYSIS

Antiepileptic Drugs MarketSize and Trends

Global Antiepileptic Drugs Market is estimated to be valued at US$ 7.01 billion in 2023, and is expected to reach US$ 8.81 billion by 2030, exhibiting a Compounded Annual Growth Rate (CAGR) of 3.3% during the forecast period (2023-2030).

Market- Trends Section: Increasing inorganic growth strategies: Increasing number of inorganic growth strategies such as collaboration  the key market players is anticipated to drive the market growth over the forecast period. For instance, in May 2021, Epilepsy Foundation, a U.S.-based non-profit national foundation, collaborated with Eisai Inc., a Japan-based pharmaceutical company, to develop the Epilepsy Digital Experience Navigator (EDEN), a platform designed to empower people with epilepsy, their caregivers, and clinicians, to use data to better understand, and improve the epilepsy journey. Approvals of new drugs by regulatory authorities: Key market players are engaged in receiving approvals from regulatory authorities, and this is expected to drive the global antiepileptic drugs market growth over the forecast period. For instance, in March 2022, UCB S.A, a global biopharmaceutical firm, announced that the U.S. Food and Drug Administration (FDA) had approved FINTEPLA (fenfluramine) oral solution CIV for the treatment of seizures associated with Lennox-Gastaut Syndrome (LGS) in patients of two years of age and older. LGS is a severe childhood-onset developmental and epileptic encephalopathy (DEE) marked by drug-refractory seizures, substantial morbidity, and significant impairment of neurodevelopmental, cognitive, and motor functioning. The second generation segment is expected to dominate the market over the forecast period, owing to the large number of ongoing clinical studies to study the efficacy of novel second generation drugs to treat seizures.